DrugPatentWatch Database Preview
Glasdegib maleate - Generic Drug Details
What are the generic sources for glasdegib maleate and what is the scope of freedom to operate?
Glasdegib maleate
is the generic ingredient in one branded drug marketed by Pfizer Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Glasdegib maleate has sixty-seven patent family members in forty-four countries.
One supplier is listed for this compound.
Summary for glasdegib maleate
| International Patents: | 67 |
| US Patents: | 3 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 5 |
| Patent Applications: | 2 |
| DailyMed Link: | glasdegib maleate at DailyMed |
Pharmacology for glasdegib maleate
| Drug Class | Hedgehog Pathway Inhibitor |
| Mechanism of Action | Smoothened Receptor Antagonists |
Synonyms for glasdegib maleate
| 1-((2R,4R)-2-(1H-Benzimidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate salt |
| 2030410-25-2 |
| D11107 |
| Daurismo |
| Glasdegib maleate (JAN) |
| PF 04449913 maleate |
| PF-04449913 maleate |
| PF-04449913 maleate salt, >=98% (HPLC) |
| SCHEMBL18171548 |
| TH2EV99S4Z |
| UNII-TH2EV99S4Z |
| Urea, N-((2R,4R)-2-(1H-benzimidazol-2-yl)-1-methyl-4-piperidinyl)-N'-(4-cyanophenyl)-, (2Z)-2-butenedioate (1:1) |
US Patents and Regulatory Information for glasdegib maleate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Start Trial | |||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-001 | Nov 21, 2018 | RX | Yes | No | Start Trial | Start Trial | Y | Y | Start Trial | ||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Pfizer Inc | DAURISMO | glasdegib maleate | TABLET;ORAL | 210656-002 | Nov 21, 2018 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for glasdegib maleate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201702238 | Start Trial |
| South Korea | 20100028120 | Start Trial |
| Costa Rica | 11150 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2016170451 | Start Trial |
| Argentina | 103632 | Start Trial |
| Panama | 8785401 | Start Trial |
| Denmark | 2170860 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2019 - 2020
NCE-1 Patent Challenge Dates 2019 - 2020
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2019, www.DrugPatentWatch.com.